Skip to main content

Subclinical Pulmonary Hypertension in Childhood Systemic Lupus Erythematosus Associated with Minor Disease Manifestations

Abstract

The aim of this study was to evaluate pulmonary hypertension (PH) in 852 childhood-onset systemic lupus erythematosus (cSLE) patients. This was a large multicenter study conducted in 10 Pediatric Rheumatology Services of São Paulo state, Brazil. PH was defined as systolic pulmonary artery pressure >35 mmHg and/or measurement of the mean pulmonary artery pressure >25 mmHg and/or diastolic pressure >15 mmHg by transthoracic echocardiogram. Demographic data, clinical manifestations, disease activity score (SLEDAI-2K), disease damage score (SLICC/ACR-DI) and treatments were also evaluated. Statistical analysis was performed using Bonferroni correction (p < 0.002). PH was observed in 17/852 (2%) cSLE patients. Effort dyspnea occurred in 3/17, chest pain in 1/17 and right ventricle dysfunction in 3/17 cSLE patients. None had pulmonary thromboembolism or antiphospholipid syndrome. Further comparison between 17 cSLE with PH and 85 cSLE control patients without PH with similar disease duration [15 (0–151) vs. 15 (0–153) months, = 0.448], evaluated at the last visit, revealed higher frequencies of fever (47 vs. 9%, p < 0.001), reticuloendothelial manifestations (41 vs. 7%, p < 0.001) and serositis (35 vs. 5%, p = 0.001) in the former group. Frequencies of renal and neuropsychiatric involvements and antiphospholipid syndrome, as well as the median of SLEDAI-2K and SLICC/ACR-DI scores, were comparable in both groups (p > 0.002). Normal transthoracic echocardiography was evidenced in 9/17 (53%), with median cSLE duration of 17.5 months (1–40) after PH standard treatment. PH was a rare manifestation of cSLE occurring in the first two years of disease. The majority of patients were asymptomatic with mild lupus manifestations. The underlying mechanism seemed not to be related to pulmonary thromboembolism and/or antiphospholipid syndrome.

This is a preview of subscription content, access via your institution.

References

  1. Veiga CS, Coutinho DS, Nakaie CM, Campos LM, Suzuki L, Cunha MT, Leone C, Silva CA, Rodrigues JC (2016) Subclinical pulmonary abnormalities in childhood-onset systemic lupus erythematosus patients. Lupus 25:645–651

    CAS  Article  PubMed  Google Scholar 

  2. Beresford MW, Cleary AG, Sills JA, Couriel J, Davidson JE (2005) Cardio-pulmonary involvement in juvenile systemic lupus erythematosus. Lupus 14:152–158

    CAS  Article  PubMed  Google Scholar 

  3. Huggins JL, Holland MJ, Brunner HI (2016) Organ involvement other than lupus nephritis in childhood-onset systemic lupus erythematosus. Lupus 25:857–863

    CAS  Article  PubMed  Google Scholar 

  4. Silva CA (2016) Childhood-onset systemic lupus erythematosus: early disease manifestations that the paediatrician must know. Expert Rev Clin Immunol 16:1–4 (Epub ahead of print)

    Google Scholar 

  5. Delgado EA, Malleson PN, Pirie GE, Petty RE (1990) The pulmonary manifestations of childhood onset systemic lupus erythematosus. Semin Arthritis Rheum 19:285–293

    CAS  Article  PubMed  Google Scholar 

  6. Ciftçi E, Yalçinkaya F, Ince E, Ekim M, Ileri M, Orgerin Z, Fitöz S, Güriz H, Aysev AD, Dogru U (2004) Pulmonary involvement in childhood-onset systemic lupus erythematosus: a report of five cases. Rheumatology 43:587–591

    Article  PubMed  Google Scholar 

  7. Khetarpal R, Goraya JS, Singh S, Singh M, Kumar L (1997) Pulmonary hypertension as presenting feature of childhood SLE: association with lupus anticoagulant. Scand J Rheumatol 26:325–326

    CAS  Article  PubMed  Google Scholar 

  8. Takatsuki S, Soep JB, Calderbank M, Ivy DD (2011) Connective tissue disease presenting with signs and symptoms of pulmonary hypertension in children. Pediatr Cardiol 32:828–833

    Article  PubMed  PubMed Central  Google Scholar 

  9. Leal GN, Silva KF, França CM, Lianza AC, Andrade JL, Campos LM, Bonfá E, Silva CA (2015) Subclinical right ventricle systolic dysfunction in childhood-onset systemic lupus erythematosus: insights from two-dimensional speckle-tracking echocardiography. Lupus 24:613–620

    CAS  Article  PubMed  Google Scholar 

  10. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725

    CAS  Article  PubMed  Google Scholar 

  11. Johnson SR, Gladman DD, Urowitz MB, Ibañez D, Granton JT (2004) Pulmonary hypertension in systemic lupus. Lupus 13:506–509

    CAS  Article  PubMed  Google Scholar 

  12. Badesch DB, Champion HC, Sanchez MA, Hoeper MM, Loyd JE, Manes A, McGoon M, Naeije R, Olschewski H, Oudiz RJ, Torbicki A (2009) Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 54:S55–S66

    Article  PubMed  Google Scholar 

  13. Nicholson GT, Samai C, Kanaan U (2013) Pulmonary hypertension in Kawasaki disease. Pediatr Cardiol 34:1966–1968

    Article  PubMed  Google Scholar 

  14. AmericanCollegeof Rheumatology Ad Hoc committee on neuropsychiatric Lupus Syndromes (1999) The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 42:599–608

    Article  Google Scholar 

  15. Avcin T, Cimaz R, Rozman B (2009) The Ped-APS Registry: the antiphospholipid syndrome in childhood. Lupus 18:894–899

    CAS  Article  PubMed  Google Scholar 

  16. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents (2004) The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 114:555–576

  17. Brandt JT, Triplett DA, Alving B, Scharrer I (1995) Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 74:1185–1190

    CAS  PubMed  Google Scholar 

  18. Gladman DD, Ibañez D, Urowitz MB (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29:288–291

    PubMed  Google Scholar 

  19. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, Bacon P, Bombardieri S, Hanly J, Hay E, Isenberg D, Jones J, Kalunian K, Maddison P, Nived O, Petri M, Richter M, Sanchez-Guerrero J, Snaith M, Sturfelt G, Symmons D, Zoma A (1996) The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 39:363–369

    CAS  Article  PubMed  Google Scholar 

  20. Pérez-Peñate GM, Rúa-Figueroa I, Juliá-Serdá G, León-Marrero F, García-Quintana A, Ortega-Trujillo JR, Erausquin-Arruabarrena C, Rodríguez-Lozano C, Cabrera-Navarro P, Ojeda-Betancor N, Gómez-Sánchez MÁ (2016) Pulmonary arterial hypertension in systemic lupus erythematosus: prevalence and predictors. J Rheumatol 43:323–329

    Article  PubMed  Google Scholar 

  21. Koestenberger M, Apitz C, Abdul-Khaliq H, Hansmann G (2016) Transthoracic echocardiography for the evaluation of children and adolescents with suspected or confirmed pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and D6PK. Heart 102(Suppl 2):ii14–ii22

    CAS  Article  PubMed  Google Scholar 

  22. Hassoun PM, Mouthon L, Barberà JA, Eddahibi S, Flores SC, Grimminger F, Jones PL, Maitland ML, Michelakis ED, Morrell NW, Newman JH, Rabinovitch M, Schermuly R, Stenmark KR, Voelkel NF, Yuan JX, Humbert M (2009) Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 54(1 Suppl):S10–S19

    CAS  Article  PubMed  Google Scholar 

  23. Li M, Wang Q, Zhao J, Li Z, Ye Z, Li C, Li X, Zhu P, Wang Z, Zheng Y, Li X, Zhang M, Tian Z, Liu Y, He J, Zhang F, Zhao Y, Zeng X, CSTAR et al (2014) Chinese SLE Treatment and Research group (CSTAR) registry: II. Prevalence and risk factors of pulmonary arterial hypertension in Chinese patients with systemic lupus erythematosus. Lupus 23:1085–1091

    Article  PubMed  Google Scholar 

  24. Min HK, Lee JH, Jung SM, Lee J, Kang KY, Kwok SK, Ju JH, Park KS, Park SH (2015) Pulmonary hypertension in systemic lupus erythematosus: an independent predictor of patient survival. Korean J Intern Med 30:232–241

    Article  PubMed  PubMed Central  Google Scholar 

  25. Kamel SR, Omar GM, Darwish AF, Asklany HT, Ellabban AS (2011) Asymptomatic pulmonary hypertension in systemic lupus erythematosus. Clin Med Insights Arthritis Musculoskelet Disord 4:77–86

    PubMed  PubMed Central  Google Scholar 

  26. Ware D, Sharma V, Kalekar L, Kamble A, Mahajan A, Gokhale Y (2015) Higher incidence of pulmonary hypertension in antiphospholipid antibody positive lupus. J Assoc Physicians India 63:17–20

    PubMed  Google Scholar 

  27. Akdogan A, Kilic L, Dogan I, Okutucu S, Er E, Kaya B, Coplu L, Calguneri M, Tokgozoglu L, Ertenli I (2013) Pulmonary hypertension in systemic lupus erythematosus: pulmonary thromboembolism is the leading cause. J Clin Rheumatol 19:421–425

    Article  PubMed  Google Scholar 

  28. Quismorio FP Jr, Sharma O, Koss M, Boylen T, Edmiston AW, Thornton PJ, Tatter D (1984) Immunopathologic and clinical studies in pulmonary hypertension associated with systemic lupus erythematosus. Semin Arthritis Rheum 13:349–359

    Article  PubMed  Google Scholar 

  29. Kommireddy S, Bhyravavajhala S, Kurimeti K, Chennareddy S, Kanchinadham S, Rajendra Vara Prasad I, Rajasekhar L (2015) Pulmonary arterial hypertension in systemic lupus erythematosus may benefit by addition of immunosuppression to vasodilator therapy: an observational study. Rheumatology 54:1673–1679

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

Our gratitude to Ulysses Doria-Filho for the statistical analysis. The authors thank the following Pediatric Rheumatology Divisions and colleagues for including their patients: Pediatric Rheumatology Unit, FMUSP (Adriana Sallum, Adriana Almeida Jesus, Cristina Miuki Abe Jacob, Gabriela Blay, Gabriella Erlacher Lube de Almeida, Heloisa Helena de Souza Marques, João Domingos Montoni da Silva, Joaquim Carlos Rodrigues, Laila Pinto Coelho, Luciana dos Santos Henriques, Lucia Campos, Mariana Ferriani, Maria Helena Vaisbich, Nadia Emi Aikawa, Roberta Cunha, Victor Marques, Werther Brunow de Carvalho); Pediatric Rheumatology Unit, UNIFESP (Ana Sakamoto, Andreia Simões Lopes, Aline Alencar, Daniela Petry Piotto, Giampaolo Faquin, Gleice Clemente, Maria Odete Esteves Hilário, Octavio Augusto Bedin Peracchi, Vanessa Bugni); Division of Rheumatology, FMUSP (Juliane A Paupitz, Glauce Leão Lima); UNESP (Priscila R. Aoki, Juliana de Oliveira Sato, Silvana Paula Cardin, Taciana Albuquerque Pedrosa Fernandes), Irmandade da Santa Casa de Misericórdia de São Paulo (Andressa Guariento, Eunice Okuda), State University of Campinas (Maraísa Centeville, Renata Barbosa, Roberto Marini), Ribeirão Preto Medical School—University of São Paulo (Francisco Hugo Gomes, Paola Pontes Pinheiro, Luciana Carvalho, Virginia Ferriani), Hospital Infantil Darcy Vargas (Jonatas Libório, Luciana Tudech Pedro Paulo, Cássia Barbosa), Hospital Municipal Infantil Menino Jesus (Tânia Caroline Monteiro de Castro) and Pontifical Catholic University of Sorocaba (Valéria C. Ramos).

Fundings

This study was supported by Grants from Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq 301805/2013-0 to RMRP, 303752/2015-7 to MTT, 301479/2015-1 to CSM, 305068/2014-8 to EB and 303422/2015-7 to CAS), Federico Foundation (to EB, RMRP and CAS) and by Núcleo de Apoio à Pesquisa “Saúde da Criança e do Adolescente” da USP (NAP-CriAd) to CAS.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Clovis A. Silva.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Anuardo, P., Verdier, M., Gormezano, N.W.S. et al. Subclinical Pulmonary Hypertension in Childhood Systemic Lupus Erythematosus Associated with Minor Disease Manifestations. Pediatr Cardiol 38, 234–239 (2017). https://doi.org/10.1007/s00246-016-1504-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00246-016-1504-6

Keywords

  • Pulmonary hypertension
  • Childhood systemic lupus erythematosus
  • Lung
  • Multicenter cohort